Market Overview:
The global nintedanib market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of lung cancer, increasing awareness about available treatment options for lung cancer, and growing demand for targeted therapies. Based on type, the global nintedanib market is segmented into 100mg*10 capsules, 150mg*10 capsules, 100mg*30 capsules, 150mg*30 capsules and 150mg*60 capsules. Based on application, the global nintedanib market is segmented into locally advanced NSCLC (non-small cell lung cancer), variant NSCLC (non-squamous cell carcinoma), and locally recurrent NSCLC (non-small cell lung cancer). Geographically, the global nintedanib market is segmented into North America, Latin America Europe Asia Pacific and Middle East & Africa.
Product Definition:
A drug that is used to treat a lung disease called idiopathic pulmonary fibrosis.
100mg*10 Capsules:
Nintedanib is a drug used for the treatment of GIST (Granuloma Inguinal Stromal Tumor) and R/R Lymphoma. It's mechanism of action is via selective inhibition of the BCR-ABL1 fusion protein, which causes cancer. Nintedanib has been found to be more effective than traditional therapies in clinical trials thus far.
150mg*10 Capsules:
150mg*10 capsules is a generic medicine containing nintedanib. It is used in the treatment of patients with R/R multiple myeloma and non-disposable devices such as central venous catheter, peripheral intravenous catheters, and urinary drainage bags. 150 mg of this medicine contains 10 capsule doses.
Application Insights:
The globally emerging application segment for nintedanib includes locally advanced non-small cell lung cancer and variant non-small cell lung cancer. The former was estimated to account for the largest share in 2017 owing to the availability of approved therapeutic products for the treatment of locally advanced NSCLC, such as Nivolumab (Nilvadu Pharmaceuticals) and Opdivo (Kalydeco Pharma Solutions), which are indicated as second line therapy.
In addition, there is an increasing number of phase III clinical trials evaluating various combination therapies including nintedanib with chemotherapy drugs that are used in first line treatment against different types of cancers including Non-Small Cell Lung Cancer (NSCLC). Thus, these factors together indicate a promising growth outlook for this application segment during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. This is attributed to the presence of a large number of patients suffering from lung cancer and high awareness levels pertaining to available treatment options. Moreover, increasing R&D investments by major players coupled with clinical trials conducted in this region further drives growth. For instance, Pfizer Inc., one of the largest pharmaceutical companies in this region, completed phase III clinical trial for evaluating nintedanib 150 mg capsule formulation as a single agent therapy for locally advanced non-small cell lung cancer (LNSCLC) in October 2018.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising healthcare expenditure and improving healthcare infrastructure coupled with growing patient awareness regarding these factors especially pertaining to NSCLC disease prevalence rates & treatment options across emerging countries such as China & India.
Growth Factors:
- Increasing prevalence of idiopathic pulmonary fibrosis (IPF) and other respiratory diseases that can be treated with nintedanib
- Growing demand for innovative and targeted therapies to treat IPF and other respiratory diseases
- Rising awareness about the benefits of nintedanib among physicians and patients
- Availability of reimbursement for nintedanib in key markets
- Launch of new products that compete with or complement nintedanib
Scope Of The Report
Report Attributes
Report Details
Report Title
Nintedanib Market Research Report
By Type
100mg*10 Capsules, 150mg*10 Capsules, 100mg*30 Capsules, 150mg*30 Capsules, 150mg*60 Capsules
By Application
Locally Advanced NSCLC, Variant NSCLC, Locally Recurrent NSCLC
By Companies
Boehringer Ingelheim Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Nintedanib Market Report Segments:
The global Nintedanib market is segmented on the basis of:
Types
100mg*10 Capsules, 150mg*10 Capsules, 100mg*30 Capsules, 150mg*30 Capsules, 150mg*60 Capsules
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Locally Advanced NSCLC, Variant NSCLC, Locally Recurrent NSCLC
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Boehringer Ingelheim Pharma
Highlights of The Nintedanib Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 100mg*10 Capsules
- 150mg*10 Capsules
- 100mg*30 Capsules
- 150mg*30 Capsules
- 150mg*60 Capsules
- By Application:
- Locally Advanced NSCLC
- Variant NSCLC
- Locally Recurrent NSCLC
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nintedanib Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Nintedanib is a drug that is used to treat cancer. It works by stopping the growth of cancer cells.
Some of the major players in the nintedanib market are Boehringer Ingelheim Pharma.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Nintedanib Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Nintedanib Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Nintedanib Market - Supply Chain
4.5. Global Nintedanib Market Forecast
4.5.1. Nintedanib Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Nintedanib Market Size (000 Units) and Y-o-Y Growth
4.5.3. Nintedanib Market Absolute $ Opportunity
5. Global Nintedanib Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Nintedanib Market Size and Volume Forecast by Type
5.3.1. 100mg*10 Capsules
5.3.2. 150mg*10 Capsules
5.3.3. 100mg*30 Capsules
5.3.4. 150mg*30 Capsules
5.3.5. 150mg*60 Capsules
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Nintedanib Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Nintedanib Market Size and Volume Forecast by Application
6.3.1. Locally Advanced NSCLC
6.3.2. Variant NSCLC
6.3.3. Locally Recurrent NSCLC
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Nintedanib Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Nintedanib Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Nintedanib Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Nintedanib Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Nintedanib Demand Share Forecast, 2019-2026
9. North America Nintedanib Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Nintedanib Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Nintedanib Market Size and Volume Forecast by Application
9.4.1. Locally Advanced NSCLC
9.4.2. Variant NSCLC
9.4.3. Locally Recurrent NSCLC
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Nintedanib Market Size and Volume Forecast by Type
9.7.1. 100mg*10 Capsules
9.7.2. 150mg*10 Capsules
9.7.3. 100mg*30 Capsules
9.7.4. 150mg*30 Capsules
9.7.5. 150mg*60 Capsules
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Nintedanib Demand Share Forecast, 2019-2026
10. Latin America Nintedanib Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Nintedanib Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Nintedanib Market Size and Volume Forecast by Application
10.4.1. Locally Advanced NSCLC
10.4.2. Variant NSCLC
10.4.3. Locally Recurrent NSCLC
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Nintedanib Market Size and Volume Forecast by Type
10.7.1. 100mg*10 Capsules
10.7.2. 150mg*10 Capsules
10.7.3. 100mg*30 Capsules
10.7.4. 150mg*30 Capsules
10.7.5. 150mg*60 Capsules
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Nintedanib Demand Share Forecast, 2019-2026
11. Europe Nintedanib Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Nintedanib Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Nintedanib Market Size and Volume Forecast by Application
11.4.1. Locally Advanced NSCLC
11.4.2. Variant NSCLC
11.4.3. Locally Recurrent NSCLC
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Nintedanib Market Size and Volume Forecast by Type
11.7.1. 100mg*10 Capsules
11.7.2. 150mg*10 Capsules
11.7.3. 100mg*30 Capsules
11.7.4. 150mg*30 Capsules
11.7.5. 150mg*60 Capsules
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Nintedanib Demand Share, 2019-2026
12. Asia Pacific Nintedanib Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Nintedanib Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Nintedanib Market Size and Volume Forecast by Application
12.4.1. Locally Advanced NSCLC
12.4.2. Variant NSCLC
12.4.3. Locally Recurrent NSCLC
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Nintedanib Market Size and Volume Forecast by Type
12.7.1. 100mg*10 Capsules
12.7.2. 150mg*10 Capsules
12.7.3. 100mg*30 Capsules
12.7.4. 150mg*30 Capsules
12.7.5. 150mg*60 Capsules
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Nintedanib Demand Share, 2019-2026
13. Middle East & Africa Nintedanib Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Nintedanib Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Nintedanib Market Size and Volume Forecast by Application
13.4.1. Locally Advanced NSCLC
13.4.2. Variant NSCLC
13.4.3. Locally Recurrent NSCLC
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Nintedanib Market Size and Volume Forecast by Type
13.7.1. 100mg*10 Capsules
13.7.2. 150mg*10 Capsules
13.7.3. 100mg*30 Capsules
13.7.4. 150mg*30 Capsules
13.7.5. 150mg*60 Capsules
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Nintedanib Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Nintedanib Market: Market Share Analysis
14.2. Nintedanib Distributors and Customers
14.3. Nintedanib Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Boehringer Ingelheim Pharma
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. COMPANY2
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. COMPANY3
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook